Literature DB >> 12447756

Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.

Timothy Schacker1, Judith Zeh, Huilin Hu, Mary Shaughnessy, Lawrence Corey.   

Abstract

In early trials of antiretroviral therapy, acyclovir was associated with increased survival by an unknown mechanism. The hypothesis that subclinical herpes simplex virus (HSV) reactivation was associated, in vivo, with increased plasma human immunodeficiency virus (HIV) RNA and suppression with a reduced plasma HIV RNA load was investigated. HSV cultures were performed daily on HSV-2-positive/HIV-positive patients, and plasma HIV-1 RNA loads were measured at regular intervals. A subset of patients prior to, during, and after HSV suppression with high-dose acyclovir was measured to determine whether HSV suppression was associated with a decrease in HIV replication. Most (25/27 HSV-2-positive/HIV-positive persons) reactivated HSV. Total HSV shedding rate was strongly correlated with plasma HIV-1 RNA load (R=0.54; P=.004), and the plasma HIV-1 RNA level at a given CD4 cell count was 48% lower when treated with acyclovir. These data indicate that frequent mucosal HSV reactivation influences HIV replication in vivo and daily HSV suppression may be important in the management of HSV-positive/HIV-positive persons.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12447756     DOI: 10.1086/345771

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  78 in total

1.  Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.

Authors:  Alison L Drake; Alison C Roxby; Francisca Ongecha-Owuor; James Kiarie; Grace John-Stewart; Anna Wald; Barbra A Richardson; Jane Hitti; Julie Overbaugh; Sandra Emery; Carey Farquhar
Journal:  J Infect Dis       Date:  2011-12-06       Impact factor: 5.226

2.  Herpes viruses and HIV-1 drug resistance mutations influence the virologic and immunologic milieu of the male genital tract.

Authors:  Sara Gianella; Sheldon R Morris; Christy Anderson; Celsa A Spina; Milenka V Vargas; Jason A Young; Douglas D Richman; Susan J Little; Davey M Smith
Journal:  AIDS       Date:  2013-01-02       Impact factor: 4.177

Review 3.  Update in HIV medicine for the generalist.

Authors:  Amina A Chaudhry; Gail Berkenblit; Allen L Gifford; Joseph Cofrancesco; James Sosman; Lynn E Sullivan
Journal:  J Gen Intern Med       Date:  2010-12-08       Impact factor: 5.128

4.  Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.

Authors:  Barb Lohman-Payne; Jennifer Slyker; Sarah L Rowland-Jones
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

5.  Efforts to Control Sexually Transmitted Infections As a Means to Limit HIV Transmission: What Is the Evidence?

Authors:  Gina Dallabetta; Graham Neilsen
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

Review 6.  Efforts to control sexually transmitted infections as a means to limit HIV transmission: what is the evidence?

Authors:  Gina Dallabetta; Graham Neilson
Journal:  Curr HIV/AIDS Rep       Date:  2004-12       Impact factor: 5.071

7.  Oral shedding of herpesviruses in HIV-infected patients with varying degrees of immune status.

Authors:  Dirk P Dittmer; Kristen Tamburro; Huichao Chen; Anthony Lee; Marcia K Sanders; Tischan A Wade; Sonia Napravnik; Jennifer Webster-Cyriaque; Mahmoud Ghannoum; Caroline H Shiboski; Judith A Aberg
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

8.  The psychosocial impact of serological herpes simplex type 2 testing in an urban HIV clinic.

Authors:  J L Meyer; R A Crosby; W L H Whittington; D Carrell; R Ashley-Morrow; A S Meier; R D Harrington; R DiClemente; A Wald
Journal:  Sex Transm Infect       Date:  2005-08       Impact factor: 3.519

9.  The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.

Authors:  Moira A McMahon; Janet D Siliciano; Jun Lai; Jun O Liu; James T Stivers; Robert F Siliciano; Rahul M Kohli
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

10.  Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

Authors:  C Celum; A Wald; J R Lingappa; A S Magaret; R S Wang; N Mugo; A Mujugira; J M Baeten; J I Mullins; J P Hughes; E A Bukusi; C R Cohen; E Katabira; A Ronald; J Kiarie; C Farquhar; G J Stewart; J Makhema; M Essex; E Were; K H Fife; G de Bruyn; G E Gray; J A McIntyre; R Manongi; S Kapiga; D Coetzee; S Allen; M Inambao; K Kayitenkore; E Karita; W Kanweka; S Delany; H Rees; B Vwalika; W Stevens; M S Campbell; K K Thomas; R W Coombs; R Morrow; W L H Whittington; M J McElrath; L Barnes; R Ridzon; L Corey
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.